Erythropoietin Stimulates Tumor Growth via EphB4.
Houston, United States. In Cancer Cell, Dec 2015
A lack of correlation between expression of the canonical EpoR and rhEpo's effects on cancer cells prompted us to consider the existence of an alternative Epo receptor.
Emerging EPO and EPO receptor regulators and signal transducers.
West Scarborough, United States. In Blood, Jul 2015
Early investigations defined basic mechanisms for hypoxia-inducible factor induction of EPO expression, and within erythroid progenitors EPOR engagement of canonical Janus kinase 2/signal transducer and activator of transcription 5 (JAK2/STAT5), rat sarcoma/mitogen-activated protein kinase/extracellular signal-regulated kinase (RAS/MEK/ERK), and phosphatidylinositol 3-kinase (PI3K) pathways.
Erythropoietin alleviates hepatic insulin resistance via PPARγ-dependent AKT activation.
Nanjing, China. In Sci Rep, 2014
Here, we report that EPO administration promoted phosphatidylinositol 3-kinase (PI3K)/AKT pathway activation in palmitic acid (PA)-treated HepG2 cells and in the liver of high-fat diet (HFD)-fed mice, whereas adenovirus-mediated silencing of the erythropoietin receptor (EPOR) blocked EPO-induced AKT signalling in HepG2 cells.
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
Memphis, United States. In N Engl J Med, 2014
Kinase-activating alterations were identified in 91% of patients with Ph-like ALL; rearrangements involving ABL1, ABL2, CRLF2, CSF1R, EPOR, JAK2, NTRK3, PDGFRB, PTK2B, TSLP, or TYK2 and sequence mutations involving FLT3, IL7R, or SH2B3 were most common.